​

NovoCure (NVCR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NVCR Stock Forecast

NovoCure (NVCR) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $28.25, with a high of $42.00 and a low of $14.50. This represents a 106.81% increase from the last price of $13.66.

$10 $17 $24 $31 $38 $45 High: $42 Avg: $28.25 Low: $14.5 Last Closed Price: $13.66

NVCR Stock Rating

NovoCure stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (60.00%), 5 Hold (33.33%), 1 Sell (6.67%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 1 5 9 Strong Sell Sell Hold Buy Strong Buy

NVCR Price Target Upside V Benchmarks

TypeNameUpside
StockNovoCure106.81%
SectorHealthcare Stocks 15.45%
IndustryMedical Instruments & Supplies Stocks15.15%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$42.00$28.25
Last Closing Price$13.66$13.66$13.66
Upside/Downside-207.47%106.81%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25142--7
Nov, 25233--8
Oct, 25233--8
Sep, 25233--8
Aug, 25233--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2025H.C. Wainwright$42.00$13.18218.66%207.47%
Jul 24, 2025Larry BiegelsenWells Fargo$14.50$12.5415.63%6.15%
Dec 02, 2024Vijay KumarEvercore ISI$30.00$26.4313.51%119.62%
Oct 16, 2024Emily BodnarH.C. Wainwright$30.00$17.7868.73%119.62%
Jul 26, 2024Emily BodnarH.C. Wainwright$24.00$18.2631.43%75.70%
May 03, 2024Emily BodnarH.C. Wainwright$22.00$14.1955.04%61.05%
May 02, 2024Vijay KumarEvercore ISI$14.50$14.78-1.89%6.15%
Apr 10, 2024Jason BednarPiper Sandler$28.00$14.8888.17%104.98%
Apr 03, 2024Larry BiegelsenWells Fargo$42.00$14.39191.87%207.47%
Mar 27, 2024H.C. Wainwright$24.00$14.6463.93%75.70%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2025H.C. WainwrightBuyBuyhold
Jan 02, 2025Evercore ISIOutperformOutperformhold
Oct 31, 2024H.C. WainwrightBuyBuyhold
Oct 16, 2024H.C. WainwrightNeutralBuyupgrade
Jul 26, 2024H.C. WainwrightNeutralNeutralhold
Jul 02, 2024Piper SandlerNeutralNeutralhold
Jun 04, 2024Wells FargoNeutralNeutralhold
May 24, 2024Piper SandlerOverweightOverweighthold
May 03, 2024H.C. WainwrightNeutralNeutralhold
May 02, 2024Wells FargoBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.20$-0.56$-0.88$-1.95$-1.56----
Avg Forecast$0.26$-0.42$-0.82$-2.02$-1.30$-1.69$-1.73$-1.43$-0.96
High Forecast$0.27$-0.40$-0.79$-1.96$-1.22$-1.43$-0.96$-1.08$-0.92
Low Forecast$0.26$-0.43$-0.85$-2.10$-1.39$-1.98$-2.66$-2.12$-0.99
Surprise %-23.08%33.33%7.32%-3.47%20.00%----

Revenue Forecast

$450M $560M $670M $780M $890M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$494.37M$535.03M$537.84M$509.34M$605.22M----
Avg Forecast$494.40M$535.00M$537.80M$509.30M$605.20M$612.96M$674.75M$797.12M$935.54M
High Forecast$507.17M$548.82M$551.17M$509.32M$605.25M$621.31M$676.70M$797.12M$958.57M
Low Forecast$484.14M$523.90M$518.23M$509.27M$605.15M$596.38M$672.80M$797.12M$906.20M
Surprise %-0.01%0.01%0.01%0.01%0.00%----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$19.81M$-58.35M$-92.53M$-207.04M$-168.63M----
Avg Forecast$27.90M$-157.76M$-55.02M$-207.04M$-138.38M$-176.86M$-179.47M$-158.73M$-102.49M
High Forecast$28.83M$-126.20M$-44.02M$-165.63M$-129.37M$-151.96M$-101.74M$-114.90M$-98.31M
Low Forecast$27.15M$-189.31M$-66.03M$-248.45M$-147.40M$-210.65M$-283.49M$-225.55M$-105.77M
Surprise %-29.00%-63.01%68.17%-21.86%----

NVCR Forecast FAQ

Is NovoCure stock a buy?

NovoCure stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 5 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that NovoCure is a favorable investment for most analysts.

What is NovoCure's price target?

NovoCure's price target, set by 15 Wall Street analysts, averages $28.25 over the next 12 months. The price target range spans from $14.5 at the low end to $42 at the high end, suggesting a potential 106.81% change from the previous closing price of $13.66.

How does NovoCure stock forecast compare to its benchmarks?

NovoCure's stock forecast shows a 106.81% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical instruments & supplies stocks industry (15.15%).

What is the breakdown of analyst ratings for NovoCure over the past three months?

  • December 2025: 14.29% Strong Buy, 57.14% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 37.50% Buy, 37.50% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 25.00% Strong Buy, 37.50% Buy, 37.50% Hold, 0% Sell, 0% Strong Sell.

What is NovoCure’s EPS forecast?

NovoCure's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.69, marking a 8.33% increase from the reported $-1.56 in 2024. Estimates for the following years are $-1.73 in 2026, $-1.43 in 2027, and $-0.96 in 2028.

What is NovoCure’s revenue forecast?

NovoCure's average annual revenue forecast for its fiscal year ending in December 2025 is $612.96M, reflecting a 1.28% increase from the reported $605.22M in 2024. The forecast for 2026 is $674.75M, followed by $797.12M for 2027, and $935.54M for 2028.

What is NovoCure’s net income forecast?

NovoCure's net income forecast for the fiscal year ending in December 2025 stands at $-177M, representing an 4.88% increase from the reported $-169M in 2024. Projections indicate $-179M in 2026, $-159M in 2027, and $-102M in 2028.